Wilson Disease

1. Clinical Overview

Summary

Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene on chromosome 13q14.3, leading to pathological copper accumulation predominantly in the liver, brain, cornea, and kidneys. The condition affects approximately 1 in 30,000 individuals worldwide, with clinical presentation typically occurring between ages 3-40 years, though peak incidence varies by phenotype: hepatic presentations commonly emerge in childhood to adolescence (5-15 years), while neuropsychiatric manifestations typically manifest in young adults (15-30 years). [1]

The hallmark of WD is impaired biliary copper excretion and defective incorporation of copper into ceruloplasmin, resulting in toxic accumulation of free copper. Clinical presentations are highly heterogeneous, ranging from asymptomatic biochemical abnormalities detected during family screening to fulminant hepatic failure requiring emergency liver transplantation. The three main phenotypic categories are: (1) hepatic WD (40-50% of cases) presenting with acute hepatitis, chronic hepatitis, cirrhosis, or acute liver failure; (2) neuropsychiatric WD (40-50%) with movement disorders (tremor, dystonia, parkinsonism), dysarthria, dysphagia, and psychiatric symptoms; and (3) presymptomatic WD detected through family screening. [2,3]

The pathognomonic ocular finding—Kayser-Fleischer (KF) rings—represents copper deposition in Descemet's membrane of the cornea and appears as golden-brown or greenish discolouration at the corneal periphery. KF rings are present in approximately 95% of patients with neurological WD but only 50-60% of those with purely hepatic presentations, emphasizing that their absence does not exclude the diagnosis. [4]

Early diagnosis and prompt initiation of lifelong copper chelation therapy (D-penicillamine, trientine) or zinc salts can halt disease progression, improve symptoms, and normalize life expectancy. Conversely, untreated WD is invariably fatal, progressing to end-stage liver disease, severe neurological disability, or both. Liver transplantation is curative for the metabolic defect and represents the only definitive treatment for acute liver failure or decompensated cirrhosis unresponsive to medical therapy. [5,6]

Key Facts

• Definition: Autosomal recessive disorder of copper metabolism due to ATP7B gene mutations
• Incidence: 1 in 30,000 live births; carrier frequency 1:90-1:100
• Peak Demographics: Presentation 3-40 years (hepatic: 5-15y; neurological: 15-30y)
• Genetics: > 500 pathogenic variants identified; H1069Q most common in Europeans
• Pathognomonic Features: Kayser-Fleischer rings + low ceruloplasmin + elevated urinary copper
• Gold Standard Diagnosis: Leipzig Score ≥4 (integrates clinical, biochemical, genetic data)
• First-line Treatment: D-penicillamine or trientine (chelation) ± zinc acetate
• Prognosis: Normal life expectancy if treated early; fatal if untreated
• Emergency: Fulminant WD requires urgent transplant assessment (high mortality)

Clinical Pearls

Diagnostic Pearl: The triad of low ceruloplasmin (less than 0.2 g/L), elevated 24-hour urinary copper (> 100 mcg/day), and Kayser-Fleischer rings on slit-lamp examination is virtually pathognomonic for Wilson disease. However, ceruloplasmin can be normal in 5-10% of cases, particularly in heterozygotes or those with acute inflammation.

Emergency Pearl: Fulminant Wilsonian crisis presents as acute liver failure with Coombs-negative haemolytic anaemia, disproportionately elevated AST/ALT ratio (> 2.2), low alkaline phosphatase, and very high serum copper. This constellation should trigger immediate transplant referral—medical therapy alone is inadequate.

Treatment Paradox Pearl: Up to 50% of patients with neurological WD experience transient worsening of neurological symptoms ("neurological deterioration paradox") during the first 3-6 months of D-penicillamine therapy. This represents mobilisation of hepatic copper stores and does NOT indicate treatment failure. Consider gradual dose escalation or switching to trientine.

Screening Pearl: All first-degree relatives of a confirmed WD patient should undergo screening (ceruloplasmin, 24h urinary copper, slit-lamp examination) regardless of age or symptoms. Siblings have a 25% risk of being affected; early detection in presymptomatic individuals dramatically improves outcomes.

Why This Matters Clinically

Wilson disease represents one of the few genuinely treatable inherited metabolic disorders. Early diagnosis and initiation of lifelong therapy can prevent irreversible hepatic and neurological damage, normalize life expectancy, and allow patients to lead normal lives. Conversely, delayed or missed diagnosis results in progressive disability and premature death. The condition must be considered in ALL young patients (less than 40 years) presenting with unexplained liver disease, movement disorders, psychiatric symptoms, or combinations thereof. Family screening is mandatory to detect presymptomatic cases.

---

2. Epidemiology

Incidence and Prevalence

Exam Detail: Ethnic and Geographic Variations:

• Higher prevalence in certain populations due to founder effects and consanguinity
• Sardinia: 1 in 2,500 (founder mutation)
• Costa Rica: 1 in 15,000
• Japan and Korea: Similar to global average
• China: Some regions report higher prevalence (1 in 10,000)
• Ashkenazi Jews: No significantly elevated risk

The H1069Q mutation accounts for 30-70% of ATP7B alleles in European populations but is rare in Asian populations, which have distinct mutation spectra. [7,8]

Age of Presentation

• Rare late presentations: Occasional cases diagnosed > 40 years, even in 6th-7th decade [9]
• Paediatric presentations: Can present as young as 3 years with hepatic disease
• Pregnancy: May unmask subclinical disease due to increased metabolic demands

Demographics

• Sex: Equal distribution in males and females
• Ethnicity: Affects all ethnic groups; mutation spectrum varies by population
• Family History:
  • 25% sibling recurrence risk (autosomal recessive)
  • Positive family history in ~20-30% of index cases
  • Remaining cases represent new mutations or incomplete family histories

---

3. Aetiology and Pathophysiology

Genetic Basis

Exam Detail: ATP7B Gene:

• Located on chromosome 13q14.3
• Encodes a P-type ATPase copper transporter (1,465 amino acids)
• Predominantly expressed in hepatocytes
• Function: Transports copper from cytoplasm into trans-Golgi network for:
  1. Incorporation into ceruloplasmin (apoceruloplasmin → holoceruloplasmin)
  2. Excretion into bile (primary route of copper elimination)

Mutation Spectrum:

• 500 pathogenic variants identified worldwide [7]

• Missense mutations (60%), frameshift/nonsense (20%), splice-site (15%), deletions (5%)
• Most patients are compound heterozygotes (two different mutations)
• Genotype-phenotype correlation is weak and unreliable for predicting clinical course

Common Mutations by Population:

• H1069Q: 30-70% of European alleles (exon 14 missense)
• R778L: Common in Asian populations
• 3402delC: Frequent in Sardinia (founder effect)
• Absence of two identified mutations does NOT exclude diagnosis (some variants in regulatory regions not routinely sequenced)

Normal Copper Homeostasis

Copper Balance:

• Daily dietary intake: 1-2 mg
• Absorption: Proximal small intestine (50-60% absorbed)
• Total body copper: 50-120 mg
• Liver copper concentration (normal): less than 50 mcg/g dry weight

Physiological Copper Handling:

1. Absorption: Intestinal enterocytes via CTR1 transporter
2. Portal Transport: Bound to albumin and amino acids
3. Hepatic Uptake: CTR1-mediated entry into hepatocytes
4. Intracellular Trafficking: Chaperone proteins (ATOX1, CCS, COX17)
5. Ceruloplasmin Synthesis: ATP7B incorporates copper into apoceruloplasmin in Golgi
6. Biliary Excretion: ATP7B transports copper to canalicular membrane for bile secretion (1-2 mg/day)

Pathophysiology of Wilson Disease

Step 1: Loss of ATP7B Function

Biallelic ATP7B mutations result in:

• Impaired copper incorporation into ceruloplasmin → low serum ceruloplasmin
• Defective biliary copper excretion → hepatic copper accumulation

Exam Detail: Ceruloplasmin Biochemistry:

• Apoceruloplasmin (copper-free) is unstable and rapidly degraded
• Holoceruloplasmin (copper-loaded) has half-life of 5-6 days
• In WD: Low/absent holoceruloplasmin → low serum ceruloplasmin (less than 0.2 g/L in 90%)
• Note: Ceruloplasmin is an acute-phase reactant; can be falsely "normal" during inflammation, pregnancy, estrogen therapy

Why Copper Accumulates:

• Biliary excretion is the ONLY significant route of copper elimination (urinary excretion minimal)
• Without functional ATP7B, copper cannot reach bile canaliculi
• Dietary copper (1-2 mg/day) continuously accumulates in hepatocytes

Step 2: Hepatic Copper Overload

• Copper accumulates initially in hepatocyte lysosomes
• Liver copper content: > 250 mcg/g dry weight (normal: less than 50 mcg/g)
• Hepatic capacity eventually exceeded (typically after years)

Step 3: Non-Ceruloplasmin-Bound Copper Release

• Once hepatic storage capacity saturated, copper released into circulation as "free" (non-ceruloplasmin-bound) copper
• Free copper is highly toxic (pro-oxidant, generates reactive oxygen species)
• Deposits in extrahepatic tissues: brain, cornea, kidneys, heart

Calculation of Free Copper:

Free Copper (μg/dL) = Total Serum Copper – (Ceruloplasmin × 3)
[Normal: less than 10 μg/dL; WD: typically > 25 μg/dL]

Step 4: Organ-Specific Damage

Exam Detail: Neurological Pathology:

• Basal Ganglia: Bilateral putaminal and lenticular necrosis, cavitation
• Thalamus: Atrophy, gliosis
• Brainstem: Pontine and mesencephalic atrophy
• Cerebral Cortex: Usually spared until late stages
• Histology: Neuronal loss, Alzheimer type II astrocytosis, Opalski cells (large astrocytes with glycogen inclusions)

Hepatic Pathology:

• Early: Steatosis (macro and microvesicular), glycogenated nuclei
• Intermediate: Portal and periportal inflammation, interface hepatitis, fibrosis
• Advanced: Cirrhosis (macro or micronodular), regenerative nodules
• Acute: Massive hepatic necrosis, bridging necrosis
• Histochemistry: Rhodanine stain highlights copper in hepatocytes; orcein stain for copper-associated protein

---

4. Clinical Presentation

Wilson disease is a "great mimicker" with protean manifestations. Clinical presentation depends on age, primary organ involvement, and disease duration.

Hepatic Presentations (40-50% of cases)

Exam Detail: Fulminant Wilsonian Crisis (Medical Emergency):

• Acute liver failure with jaundice, coagulopathy, encephalopathy
• Coombs-negative haemolytic anaemia (pathognomonic combination)
• Very high serum copper (> 200 mcg/dL) and urinary copper (> 1000 mcg/24h)
• Low alkaline phosphatase (less than 40 U/L) due to hepatocyte necrosis
• AST/ALT ratio typically > 2.2 (ratio > 4 highly suggestive) [10]
• Alkaline phosphatase/total bilirubin ratio less than 4 is 94% specific for Wilsonian crisis
• Rapid progression; medical therapy inadequate → emergency liver transplantation
• Mortality > 90% without transplantation

King's College Criteria (Modified for Wilson Disease): Not specifically validated for WD, but transplant should be considered when:

• INR > 2.0
• Rising bilirubin despite treatment
• Progressive encephalopathy
• Renal failure

New Wilson Index (Nazer Score): Predicts need for transplantation; score ≥11 indicates poor prognosis without transplant:

• Bilirubin (mg/dL) × 1 point
• INR × 10 points
• AST (U/L) × 0.01 points
• WBC (×10³/μL) × 1 point
• Albumin (g/dL) × (-1) points [Score ≥11: sensitivity 93%, specificity 98% for death without transplant] [11]

Neuropsychiatric Presentations (40-50% of cases)

Neurological Features:

Psychiatric Features (present in 30-100% of neurological WD):

Exam Detail: Neurological Examination Findings:

• Tremor: Best elicited with arms outstretched (wing-beating) or with finger-nose testing
• Dystonia: Facial grimacing, torticollis, limb dystonia; may be task-specific
• Dysarthria: Scanning speech, hypophonia, monotone, drooling
• Parkinsonism: Cogwheel rigidity, bradykinesia, reduced facial expression, shuffling gait
• Gait: Wide-based, unsteady, slow, reduced arm swing
• Reflexes: Variable; may be normal, brisk, or reduced
• Kayser-Fleischer rings: Visible with slit-lamp in 95% of neurological WD (see below)

"Flapping Tremor" Misnomer: The classic "wing-beating tremor" is NOT asterixis (which is a metabolic tremor seen in hepatic encephalopathy). Wing-beating tremor in WD is a proximal, rhythmic, coarse tremor elicited by shoulder abduction and elbow flexion, resembling a bird flapping wings.

Ophthalmological Features

Kayser-Fleischer (KF) Rings:

• Golden-brown or greenish copper deposition in Descemet's membrane (peripheral cornea)
• Begins at superior cornea, then inferior, eventually forms complete ring
• Slit-lamp examination required for definitive detection (not visible to naked eye in early stages)
• Prevalence:
  • "Neurological WD: 95-100%"
  • "Hepatic WD: 50-65%"
  • "Presymptomatic WD: 20-30%"
• Absence does NOT exclude WD, especially in pure hepatic presentations
• KF rings may fade or disappear with successful chelation therapy

Sunflower Cataracts:

• Copper deposition in lens capsule
• Radial, petal-like pattern (resembles sunflower)
• Less common than KF rings (10-20%)
• Does not affect vision
• More common in chronic WD

Other Systemic Features

Patterns of Presentation

Exam Detail: Phenotypic Categories [2]:

1. Hepatic predominant: Liver disease ± minimal neurological signs; younger age
2. Neurological predominant: Movement disorder ± mild liver disease; older age
3. Mixed hepatoneurological: Both hepatic and neurological features
4. Presymptomatic: Detected via family screening; normal examination or subtle findings
5. Rare presentations: Isolated haemolysis, renal disease, cardiac involvement

Age-Related Presentation Patterns:

• Children (3-10 years): Almost exclusively hepatic; often asymptomatic transaminitis
• Adolescents (10-20 years): Hepatic or mixed; increasing neuropsychiatric features
• Young Adults (20-30 years): Predominantly neuropsychiatric; often with established cirrhosis
• Adults (> 30 years): Variable; late diagnosis often involves neurological or psychiatric manifestations

Red Flags (Emergency Features)

[!CAUTION] Red Flags Requiring Urgent Assessment

• Young patient (less than 40 years) with unexplained cirrhosis → Screen for WD
• Acute liver failure + Coombs-negative haemolysis → Fulminant WD; emergency transplant referral
• Movement disorder + liver disease in young adult → WD until proven otherwise
• AST/ALT ratio > 2.2 with acute hepatitis → Suggests Wilsonian crisis
• Alkaline phosphatase/bilirubin less than 4 in acute liver failure → Highly specific for WD
• Kayser-Fleischer rings in patient with neuropsychiatric symptoms → Virtually diagnostic
• Family history of unexplained liver disease or young-onset movement disorder → Screen for WD

---

5. Differential Diagnosis

Wilson disease must be distinguished from other causes of liver disease, movement disorders, and psychiatric illness.

Hepatic Presentations

Comparison Table: Wilson Disease vs Autoimmune Hepatitis

Neurological Presentations

Comparison Table: Wilson Disease vs Parkinson Disease

Psychiatric Presentations

Key Principle: Always screen for WD in young patients (less than 40 years) with new-onset psychiatric symptoms, especially if accompanied by movement disorder, liver disease, or family history.

---

6. Investigations

Screening Tests

Exam Detail: Ceruloplasmin Interpretation:

• Low (less than 0.2 g/L): Seen in 90% of WD, but also in:
  • Heterozygous carriers (10-20% have low-normal ceruloplasmin)
  • Severe liver disease (any cause)
  • Nephrotic syndrome
  • Protein-losing enteropathy
  • Malnutrition
  • Aceruloplasminaemia (rare genetic disorder)
• Normal (0.2-0.4 g/L): Does NOT exclude WD (5-10% of patients have "normal" ceruloplasmin)
  • Acute inflammation (ceruloplasmin is acute-phase reactant)
  • Pregnancy, estrogen therapy
  • Heterozygotes

24-Hour Urinary Copper Interpretation:

• Normal (less than 40 mcg/day): Unlikely to be WD (but can occur in presymptomatic patients)
• Borderline (40-100 mcg/day): Suggestive; consider repeat, d-penicillamine challenge
• Elevated (> 100 mcg/day): Highly suggestive of WD
• Very High (> 1000 mcg/day): Seen in fulminant WD
• False positives: Cholestatic liver disease, chronic active hepatitis, nephrotic syndrome

Penicillamine Challenge Test (if urinary copper borderline):

• Administer 500 mg D-penicillamine PO at 0h and 12h
• Collect urine 0-24h for copper
• Interpretation: > 25-fold increase or total > 1600 mcg/24h strongly suggests WD
• Use limited; genetic testing now preferred

Advanced Biochemical Tests

Leipzig Scoring System

The Leipzig Score integrates clinical, biochemical, and genetic data to diagnose WD. [12]

Interpretation:

• Score ≥4: Diagnosis of WD established
• Score 3: Diagnosis possible; further investigations required
• Score ≤2: Diagnosis unlikely (but not excluded; consider repeat testing, genetic studies)

Exam Detail: Advantages of Leipzig Score:

• Quantitative, reproducible
• Integrates multiple diagnostic parameters
• Useful when individual tests equivocal
• Validated in large cohorts

Limitations:

• Requires complete data set (often liver biopsy and genetic testing not immediately available)
• Genetic testing may not identify all mutations (novel variants, intronic mutations)
• Does not replace clinical judgment

Imaging

MRI Brain (T2-weighted, FLAIR sequences):

Liver Imaging (Ultrasound, CT, MRI):

• Variable findings: normal, steatosis, hepatomegaly, cirrhosis, nodular liver
• Not specific for WD
• Used to assess liver architecture, portal hypertension, exclude HCC

Abdominal Ultrasound:

• Assess liver size, echogenicity, nodularity
• Evaluate spleen (splenomegaly suggests portal hypertension)
• Assess for ascites

Liver Biopsy

Indications:

• Diagnosis uncertain based on non-invasive tests
• Assess severity of liver disease (fibrosis staging)
• Quantitative hepatic copper measurement (gold standard)

Findings:

• Hepatic Copper Content: > 250 mcg/g dry weight (normal: less than 50 mcg/g) diagnostic
• Histology:
  • Steatosis (macro/microvesicular)
  • Portal/periportal inflammation
  • Interface hepatitis (resembles autoimmune hepatitis)
  • Fibrosis (variable stages)
  • Cirrhosis (advanced cases)
  • Glycogenated nuclei
  • Mallory-Denk bodies (rare)
• Histochemistry:
  • "Rhodanine stain: Highlights copper deposits (reddish granules)"
  • "Orcein stain: Copper-associated protein (brown granules)"

Limitations:

• Copper distribution may be heterogeneous (sampling error)
• Elevated copper also seen in cholestatic liver diseases
• Invasive procedure with risks

Genetic Testing

ATP7B Gene Sequencing:

• Detects > 95% of pathogenic mutations in coding regions
• Confirms diagnosis if 2 pathogenic variants identified
• Useful for family screening, prenatal diagnosis
• Negative result does NOT exclude WD (intronic/regulatory mutations may not be detected)

Approach:

• Targeted mutation analysis (if specific population/family mutation known)
• Full gene sequencing (exons + splice sites)
• Deletion/duplication analysis if sequencing negative

Screening First-Degree Relatives

Recommended Protocol [6]:

1. Serum ceruloplasmin (low in 90% of affected)
2. 24-hour urinary copper (elevated in affected)
3. Slit-lamp examination (KF rings in presymptomatic individuals)
4. ATP7B genetic testing (if index case mutations known)
5. Liver function tests (ALT, AST, bilirubin)

Interpretation:

• If all tests normal → unlikely to be affected (but repeat in 1-2 years if young)
• If abnormal → proceed to full diagnostic workup

---

7. Management

Wilson disease requires lifelong treatment. Goals: reduce copper accumulation, prevent disease progression, improve symptoms.

General Principles

1. Lifelong Therapy: Treatment must continue indefinitely; discontinuation leads to relapse and death
2. Individualized Regimen: Choice of initial therapy depends on phenotype, severity, tolerance
3. Monitoring: Regular biochemical, clinical, and ophthalmological follow-up mandatory
4. Avoid Copper: Dietary restriction, avoid copper-containing supplements
5. Family Screening: Screen all first-degree relatives

Pharmacological Treatment

Exam Detail: Treatment Algorithm:

Wilson Disease Diagnosis Confirmed
    |
    ├─> Presymptomatic / Mild Hepatic
    |       └─> Zinc Acetate (First-line)
    |            OR Trientine (if zinc not tolerated)
    |
    ├─> Symptomatic Hepatic (No Liver Failure)
    |       └─> D-Penicillamine OR Trientine
    |            (Start low, escalate gradually)
    |            Add Zinc after 3-6 months
    |
    ├─> Neurological Presentation
    |       └─> Trientine (preferred) OR D-Penicillamine (low dose)
    |            CAUTION: Risk neurological worsening
    |            Add Zinc after 3-6 months
    |
    ├─> Fulminant Hepatic Failure
    |       └─> Emergency Liver Transplantation
    |            (Chelation insufficient)
    |
    └─> Maintenance (After Stabilization)
            └─> Zinc Monotherapy
                 OR Low-dose Chelator + Zinc

1. Chelation Therapy

D-Penicillamine (First-line chelator):

Trientine (Triethylene tetramine dihydrochloride):

Exam Detail: Neurological Worsening Paradox:

• 20-50% of patients with neurological WD experience worsening of neurological symptoms during initial 3-6 months of chelation (especially D-penicillamine)
• Mechanism: Rapid mobilization of hepatic copper → transient increase in free serum copper → brain deposition
• Clinical features: Worsening tremor, dystonia, dysarthria, gait instability
• Management:
  1. Reassure patient (usually transient, resolves after 6-12 months)
  2. Continue treatment (discontinuation worsens outcome)
  3. Consider dose reduction, slow escalation
  4. Switch to trientine if severe worsening
  5. Add zinc acetate
• Prevention: Start with low doses, gradual escalation; consider trientine as first-line in neurological patients

2. Zinc Therapy

Zinc Acetate (or Zinc Sulfate):

Combination Therapy:

• Chelator (penicillamine or trientine) for initial de-coppering (6-12 months)
• Add zinc after 3-6 months
• Transition to zinc monotherapy for long-term maintenance (once stable)

3. Tetrathiomolybdate (Investigational)

Liver Transplantation

Indications:

1. Fulminant Hepatic Failure (Wilsonian Crisis):
   • Acute liver failure + Coombs-negative haemolysis
   • Medical therapy inadequate
   • Emergency transplantation required (highest priority listing)
2. Decompensated Cirrhosis:
   • Refractory ascites, variceal bleeding, hepatorenal syndrome
   • No improvement despite 3-6 months chelation therapy
3. Hepatocellular Carcinoma (rare in WD but can occur)

Outcomes:

• 5-year survival: 80-90% [13]
• Curative: Corrects metabolic defect (donor liver has normal ATP7B)
• Neurological symptoms may improve post-transplant (but slower than hepatic features)
• Lifelong immunosuppression required

Prognostic Scores for Transplant Decision:

• New Wilson Index (Nazer Score): ≥11 predicts death without transplant
• King's College Criteria (adapted): Encephalopathy + INR > 2.0
• MELD Score: Standard liver transplant prioritization

Exam Detail: Transplant Controversies:

• Should liver transplantation be offered for isolated neurological WD refractory to medical therapy?
  • Controversial; some centres offer transplant for severe, progressive neurological disease
  • Evidence limited; neurological improvement variable
  • Risk of immunosuppression vs. potential benefit

Dietary Management

Dietary Copper Restriction (especially during initial treatment):

Additional Advice:

• Avoid copper-containing multivitamins/supplements
• Check drinking water copper content (if copper pipes, may need filtration)
• Use stainless steel or non-copper cookware

Monitoring During Treatment

Treatment Targets:

• Clinical: Symptom stabilization or improvement
• Biochemical: 24h urinary copper 50-150 mcg/day (maintenance); free copper 5-15 mcg/dL
• Ophthalmological: Fading of KF rings (may take years)

Special Populations

Pregnancy [14]:

• Continue treatment throughout pregnancy (discontinuation risks maternal/fetal harm)
• Zinc acetate: Safest option; first-line in pregnancy
• D-penicillamine: Continue if already on (reduce dose to 750-1000 mg/day); associated with connective tissue abnormalities in fetus (rare); benefits usually outweigh risks
• Trientine: Limited data; probably safe; continue if already on
• Monitoring: More frequent monitoring (monthly)
• Delivery: No specific contraindications; vaginal delivery safe

Children:

• Doses adjusted for weight
• Zinc: 25 mg TDS
• Penicillamine/Trientine: 20 mg/kg/day (divided doses)
• Monitor growth, development

Elderly:

• Rare late presentations
• Adjust doses for renal function, comorbidities
• Monitor for drug interactions

Non-Compliance

• Major cause of treatment failure and relapse
• Factors: Lifelong therapy burden, side effects, lack of symptoms (presymptomatic patients)
• Consequences: Relapse of liver/neurological disease; acute liver failure
• Strategies: Education, regular follow-up, pill counts, urinary copper monitoring (low urinary copper suggests non-compliance)

---

8. Complications

Hepatic Complications

Neurological Complications

Renal Complications

Haematological Complications

Skeletal Complications

---

9. Prognosis

With Treatment

• Early Diagnosis (Presymptomatic/Early Symptomatic):

  • Excellent prognosis
  • Normal life expectancy with adherence to therapy [6]
  • Hepatic disease stabilizes or improves
  • Neurological symptoms may stabilize (may not fully reverse)
  • KF rings may fade or disappear

• Symptomatic at Diagnosis:

  • Variable outcomes depending on severity
  • "Hepatic: Good response if pre-cirrhotic; slower improvement if cirrhotic"
  • "Neurological: Improvement over months to years; residual disability common"
  • Psychiatric symptoms often improve with treatment

• Advanced Disease (Cirrhosis, Neurological Disability):

  • Stabilization possible but reversal limited
  • Ongoing monitoring for complications (varices, HCC)
  • Quality of life depends on residual symptoms

Without Treatment

• Uniformly Fatal
• Progression to:
  • End-stage liver disease (hepatic failure)
  • Severe neurological disability (wheelchair-bound, anarthria)
  • Death (usually hepatic or neurological deterioration)
• Median survival untreated: less than 5 years from symptom onset

Factors Affecting Prognosis

Post-Transplant Prognosis

• 5-year survival: 80-90% [13]
• Curative for metabolic defect
• Neurological symptoms may improve (but slower than hepatic features)
• Lifelong immunosuppression required (associated risks)

---

10. Prevention and Screening

Primary Prevention

• No primary prevention (genetic disorder)
• Genetic counseling for families with known WD

Secondary Prevention (Early Detection)

Family Screening:

• All first-degree relatives (siblings, children) of index case should be screened [6]
• Screening Tests:
  1. Serum ceruloplasmin
  2. 24-hour urinary copper
  3. Slit-lamp examination
  4. Liver function tests
  5. ATP7B genetic testing (if index mutations known)
• Timing: As soon as diagnosis in index case confirmed; repeat in childhood if initially normal
• Outcome: Early treatment of presymptomatic individuals prevents disease manifestations

Cascade Screening:

• If sibling affected, screen their children (index case's nieces/nephews)

Tertiary Prevention (Prevent Complications)

• Lifelong treatment adherence: Prevent relapse
• Regular monitoring: Detect complications early (varices, HCC)
• Avoid hepatotoxins: Alcohol, hepatotoxic drugs
• Vaccination: Hepatitis A and B (protect liver)
• Surveillance:
  • Variceal screening (endoscopy) if cirrhotic
  • HCC surveillance (6-monthly ultrasound + AFP) if cirrhotic

---

11. Key Guidelines and Evidence

Major Guidelines

1. European Association for the Study of the Liver (EASL) 2012 [3]:

   • Comprehensive diagnostic and management guidelines
   • Leipzig Score for diagnosis
   • Treatment recommendations (chelation, zinc, transplant)

2. American Association for the Study of Liver Diseases (AASLD) 2008 [1]:

   • Diagnostic criteria
   • Treatment algorithms
   • Transplant indications

3. British Society of Gastroenterology (BSG) Guidelines (upcoming update expected)

Landmark Studies

• Walshe JS. Lancet 1956 [15]: First description of penicillamine treatment for WD
• Brewer GJ et al. Arch Neurol 1991 [16]: Zinc acetate efficacy in WD
• Ferenci P et al. Gastroenterology 2003 [12]: Development and validation of Leipzig Score
• Litwin T et al. Mov Disord 2012 [17]: Characterization of neurological worsening with chelation

---

12. Examination Focus

Viva Pearls

Opening Statement: "Wilson disease is an autosomal recessive disorder of copper metabolism caused by ATP7B gene mutations on chromosome 13, leading to impaired biliary copper excretion and defective ceruloplasmin synthesis. This results in toxic copper accumulation in the liver, brain, cornea, and other organs. It presents with hepatic disease, neuropsychiatric symptoms, or both, typically in young adults. Early diagnosis and lifelong copper chelation therapy are essential; untreated disease is fatal."

Common Viva Questions and Model Answers

Q1: How do you diagnose Wilson disease?

"Diagnosis is based on a combination of clinical features, biochemical tests, and genetic analysis. The Leipzig Score integrates these parameters. Key investigations include: (1) serum ceruloplasmin—low (less than 0.2 g/L) in 90% of cases, though can be normal; (2) 24-hour urinary copper—elevated (> 100 mcg/day) in untreated WD; (3) slit-lamp examination for Kayser-Fleischer rings—present in 95% of neurological WD and 50% of hepatic WD; (4) serum free copper—calculated as total copper minus ceruloplasmin-bound copper, elevated in WD; (5) liver copper content on biopsy (if feasible)—> 250 mcg/g dry weight is diagnostic; and (6) ATP7B genetic testing—detection of two pathogenic mutations confirms diagnosis. A Leipzig Score ≥4 establishes the diagnosis."

Q2: What is the pathophysiology of copper accumulation in Wilson disease?

"ATP7B is a copper-transporting ATPase located in hepatocytes. It has two critical functions: (1) incorporating copper into apoceruloplasmin in the Golgi to form holoceruloplasmin, and (2) transporting copper to the bile canaliculus for excretion into bile, which is the primary route of copper elimination. In WD, loss-of-function mutations in ATP7B impair both processes. This leads to reduced serum ceruloplasmin (apoceruloplasmin is unstable and degraded) and impaired biliary copper excretion. Consequently, copper accumulates in hepatocytes. Over time, hepatic storage capacity is exceeded, and copper is released into the bloodstream as toxic non-ceruloplasmin-bound 'free' copper, which deposits in extrahepatic tissues—particularly the brain (basal ganglia), cornea (Kayser-Fleischer rings), and kidneys—causing oxidative damage and organ dysfunction."

Q3: Describe the clinical presentations of Wilson disease.

"WD has three main phenotypes. (1) Hepatic: Ranges from asymptomatic transaminitis to acute hepatitis, chronic hepatitis, cirrhosis, or fulminant hepatic failure. Fulminant WD (Wilsonian crisis) presents with acute liver failure, Coombs-negative haemolytic anaemia, very high serum copper, and high AST/ALT ratio (> 2.2)—this is a medical emergency requiring transplant. (2) Neuropsychiatric: Movement disorders (tremor—often 'wing-beating', dystonia, parkinsonism), dysarthria, dysphagia, psychiatric symptoms (depression, behavioural changes, psychosis), and cognitive impairment. Kayser-Fleischer rings are present in 95% of neurological cases. (3) Presymptomatic: Detected via family screening; may have subtle biochemical or ophthalmological findings but no overt symptoms. Presentations typically occur age 5-40 years, with hepatic earlier (5-15y) and neurological later (15-30y)."

Q4: What are the treatment options for Wilson disease?

"Treatment aims to reduce copper accumulation and is lifelong. Options include: (1) Chelation therapy—D-penicillamine or trientine. Penicillamine (1000-1500 mg/day) is highly effective but has significant side effects (hypersensitivity, proteinuria, bone marrow suppression) and can cause neurological worsening in 20-50% of patients. Trientine (750-1500 mg/day) is better tolerated and preferred in neurological WD. (2) Zinc therapy—zinc acetate (150 mg elemental zinc/day) blocks intestinal copper absorption and is used for maintenance therapy or in presymptomatic patients. It's safe in pregnancy. (3) Combination therapy—initial chelation for de-coppering (6-12 months), then transition to zinc monotherapy or low-dose chelator plus zinc. (4) Liver transplantation—curative; indicated for fulminant hepatic failure or decompensated cirrhosis unresponsive to medical therapy. (5) Dietary copper restriction—avoid shellfish, liver, nuts, chocolate. Treatment adherence is critical; non-compliance causes relapse."

Q5: What is the neurological worsening paradox?

"Up to 50% of patients with neurological WD experience paradoxical worsening of neurological symptoms during the first 3-6 months of chelation therapy, particularly with D-penicillamine. The mechanism is thought to be rapid mobilization of hepatic copper stores, causing a transient increase in free serum copper that deposits in the brain. Clinically, patients develop worsening tremor, dystonia, dysarthria, or gait instability. This is NOT treatment failure. Management includes: reassuring the patient that it's usually transient, continuing treatment (discontinuation worsens outcomes), considering dose reduction or slow escalation, switching to trientine (lower risk), and adding zinc acetate. Prevention strategies include starting with low chelator doses and gradual escalation, or using trientine as first-line in neurological patients."

Q6: What are Kayser-Fleischer rings and how are they detected?

"Kayser-Fleischer (KF) rings are pathognomonic for WD and represent copper deposition in Descemet's membrane at the corneal periphery. They appear as golden-brown or greenish discolouration, typically starting superiorly, then inferiorly, eventually forming a complete ring. KF rings are detected by slit-lamp examination by an ophthalmologist—they are not reliably visible to the naked eye, especially in early stages or in lightly pigmented irides. Prevalence varies by phenotype: present in 95% of neurological WD but only 50-60% of purely hepatic WD, and 20-30% of presymptomatic cases. Importantly, absence of KF rings does NOT exclude WD, especially in hepatic presentations. KF rings may fade or disappear with successful chelation therapy."

Q7: How do you screen first-degree relatives?

"All first-degree relatives (siblings, children) of a confirmed WD patient should undergo screening, as siblings have a 25% recurrence risk. The screening protocol includes: (1) serum ceruloplasmin—low in 90% of affected individuals; (2) 24-hour urinary copper—elevated in affected; (3) slit-lamp examination—to detect KF rings; (4) liver function tests (ALT, AST, bilirubin); and (5) ATP7B genetic testing—especially useful if the index case's mutations are known, allowing direct genotyping. If all tests are normal, the individual is unlikely to be affected, but repeat testing in 1-2 years is advised, especially in children. Early detection of presymptomatic individuals allows initiation of treatment before irreversible damage occurs, dramatically improving outcomes."

Q8: When is liver transplantation indicated?

"Liver transplantation is indicated in two main scenarios: (1) Fulminant hepatic failure (Wilsonian crisis)—acute liver failure with Coombs-negative haemolysis, high AST/ALT ratio, low alkaline phosphatase. This is a medical emergency; chelation alone is inadequate. Transplant assessment should be immediate, and these patients are listed as highest priority. Prognostic scores like the New Wilson Index (Nazer score ≥11) predict death without transplant. (2) Decompensated cirrhosis—refractory ascites, variceal bleeding, hepatorenal syndrome, or progressive liver failure despite 3-6 months of chelation therapy. Transplantation is curative for the metabolic defect (donor liver has normal ATP7B), with 5-year survival of 80-90%. Neurological symptoms may also improve post-transplant, though more slowly than hepatic features. Lifelong immunosuppression is required."

Clinical Examination Stations

Long Case Scenario: Young adult with movement disorder and liver disease

Presenting Complaint: 24-year-old male with 18-month history of progressive tremor, slurred speech, and recent jaundice.

Examination Findings:

• General: Jaundiced, cachectic
• Hands: Coarse tremor at rest and with posture; "wing-beating" tremor with arms outstretched
• Face: Mask-like facies, drooling, dysarthria
• Eyes: Slit-lamp reveals golden-brown KF rings bilaterally
• Abdomen: Hepatosplenomegaly, mild ascites
• Neurology: Cogwheel rigidity, bradykinesia, wide-based gait

Key Points to Mention:

• Combination of neurological (movement disorder) and hepatic (cirrhosis) features in young adult strongly suggests Wilson disease
• KF rings are pathognomonic
• Differential diagnosis: Parkinson disease (but too young, no KF rings, no liver disease), Huntington disease (chorea predominant, no liver disease)
• Investigations: Ceruloplasmin, 24h urinary copper, liver copper, ATP7B genetics, MRI brain
• Management: Chelation (trientine preferred given neurological features), zinc, monitor for neurological worsening, consider transplant if decompensated
• Screen first-degree relatives

Common Exam Mistakes

• ❌ Assuming normal ceruloplasmin excludes WD (5-10% have normal levels)
• ❌ Assuming absence of KF rings excludes WD (only 50% of hepatic WD have KF rings)
• ❌ Discontinuing treatment when neurological symptoms worsen initially (neurological worsening paradox is expected)
• ❌ Not screening first-degree relatives
• ❌ Not considering WD in young patient with unexplained liver disease, movement disorder, or psychiatric symptoms
• ❌ Forgetting to mention lifelong treatment requirement
• ❌ Not recognizing fulminant WD as a transplant emergency

---

13. Patient Explanation (Layperson Language)

What is Wilson Disease?

"Wilson disease is a rare inherited condition where your body cannot get rid of copper properly. We all need a tiny amount of copper from our diet, but in Wilson disease, copper builds up over time, mainly in your liver and brain, and can damage these organs."

Why Does It Happen?

"You inherit Wilson disease from your parents. It's caused by a change (mutation) in a gene called ATP7B. This gene normally helps your liver get rid of extra copper through bile (a digestive fluid). When the gene doesn't work properly, copper accumulates instead of being removed. Both parents need to carry the gene for you to have Wilson disease—you inherit one faulty gene from each parent."

What Are the Symptoms?

"Symptoms usually start in teenagers or young adults, but can appear in children or older adults. Wilson disease can affect different parts of your body:

• Liver problems: Tiredness, yellowing of the skin or eyes (jaundice), swollen belly, feeling unwell. Some people have no symptoms but blood tests show liver damage.
• Movement and brain problems: Shaking hands (tremor), stiffness, difficulty walking, slurred speech, trouble swallowing, mood changes, depression, memory problems.
• Eyes: Golden-brown rings around the colored part of your eye (called Kayser-Fleischer rings). You can't see these yourself—an eye doctor finds them with a special lamp. They don't affect your vision.

Some people are diagnosed before symptoms start, through family screening."

How Is It Diagnosed?

"Your doctor will do several tests:

• Blood tests: Check ceruloplasmin (a protein that carries copper—it's usually low in Wilson disease) and copper levels.
• Urine test: Measure how much copper your body is getting rid of (it's high in Wilson disease).
• Eye examination: An eye doctor uses a slit-lamp to look for Kayser-Fleischer rings.
• Genetic test: Check for the gene mutation.
• Sometimes a liver biopsy (small sample of liver tissue) or brain scan (MRI) is needed."

How Is It Treated?

"The good news is Wilson disease is treatable. Treatment removes extra copper from your body and prevents new copper from building up. You need to take medication for the rest of your life.

• Chelation tablets (like D-penicillamine or trientine): These bind to copper in your body and help remove it through urine. You take them on an empty stomach every day.
• Zinc tablets: These block your intestines from absorbing copper from food. Often used for long-term treatment or in combination with chelation.
• Diet changes: Avoid foods high in copper (like shellfish, liver, nuts, chocolate, mushrooms).

Important: Never stop your medication without talking to your doctor. Stopping treatment can cause serious relapse and harm to your liver and brain.

Some people experience worsening symptoms (especially tremor or stiffness) when starting treatment—this is temporary and doesn't mean the treatment isn't working. Your doctor will monitor you closely."

What If Treatment Doesn't Work?

"In rare severe cases (like sudden liver failure), a liver transplant may be needed. A transplant cures the copper problem because the new liver works normally."

What Happens If Wilson Disease Is Not Treated?

"Without treatment, Wilson disease gets worse over time and can cause severe liver damage (cirrhosis, liver failure) or severe brain and movement problems. Untreated Wilson disease is life-threatening. With treatment, most people live normal, healthy lives."

What About My Family?

"Wilson disease runs in families. If you have Wilson disease, your brothers, sisters, and children should be tested, even if they feel well. Early detection and treatment can prevent symptoms from ever developing."

Living With Wilson Disease

• Take your medication every day as prescribed
• Attend regular check-ups with your doctor
• Avoid alcohol (it can damage your liver further)
• Eat a balanced diet and avoid high-copper foods
• Tell other doctors and dentists you have Wilson disease
• Carry medical alert information
• If you're planning a pregnancy, talk to your doctor—treatment needs to continue but doses may be adjusted

Remember: Wilson disease is manageable with lifelong treatment. Early diagnosis and adherence to therapy mean you can live a full, normal life.

---

14. References

1. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089-2111. doi:10.1002/hep.22261. PMID: 18506894

2. Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103-113. doi:10.1016/S1474-4422(14)70190-5. PMID: 25496898

3. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56(3):671-685. doi:10.1016/j.jhep.2011.11.007. PMID: 22340672

4. Rodríguez-Castro KI, Hevia-Urrutia FJ, Sturniolo GC. Wilson's disease: A review of what we have learned. World J Hepatol. 2015;7(29):2859-2870. doi:10.4254/wjh.v7.i29.2859. PMID: 26689333

5. Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson's disease. Ann N Y Acad Sci. 2014;1315:81-85. doi:10.1111/nyas.12455. PMID: 24820352

6. Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom. Brain. 2013;136(Pt 5):1476-1487. doi:10.1093/brain/awt035. PMID: 23518715

7. Kenney SM, Cox DW. Sequence variation database for the Wilson disease copper transporter, ATP7B. Hum Mutat. 2007;28(12):1171-1177. doi:10.1002/humu.20586. PMID: 17680703

8. Pfeiffer RF. Wilson's Disease. Semin Neurol. 2007;27(2):123-132. doi:10.1055/s-2007-971173. PMID: 17390257

9. Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci. 2010;1184:173-187. doi:10.1111/j.1749-6632.2009.05109.x. PMID: 20146697

10. Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2008;48(4):1167-1174. doi:10.1002/hep.22446. PMID: 18798626

11. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27(11):1377-1381. doi:10.1136/gut.27.11.1377. PMID: 3792921

12. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-142. doi:10.1034/j.1600-0676.2003.00824.x. PMID: 12955875

13. Medici V, Rossaro L, Sturniolo GC. Wilson disease--a practical approach to diagnosis, treatment and follow-up. Dig Liver Dis. 2007;39(7):601-609. doi:10.1016/j.dld.2006.12.095. PMID: 17324633

14. Brewer GJ, Johnson VD, Dick RD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology. 2000;31(2):364-370. doi:10.1002/hep.510310214. PMID: 10655259

15. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21(4):487-495. doi:10.1016/0002-9343(56)90066-3. PMID: 13362281

16. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132(4):264-278. doi:10.1016/s0022-2143(98)90042-8. PMID: 9794699

17. Litwin T, Gromadzka G, Członkowska A. Gender differences in Wilson's disease. J Neurol Sci. 2012;312(1-2):31-35. doi:10.1016/j.jns.2011.08.028. PMID: 21925683

18. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet. 2007;369(9559):397-408. doi:10.1016/S0140-6736(07)60196-2. PMID: 17276780

---